BioSpectrum
the business of Bio & Health Sciences

Indian pharma market records 10.6% growth in December 2025: Pharmarack

09 January 2026 | News

Growth during the month was largely value-led, supported by modest unit expansion

Image not found or type unknown

The Indian Pharma Market (IPM) recorded a healthy growth trajectory in December 2025, supported by strong performances from leading pharmaceutical companies, according to PHARMARACK MAT December 2025 data. The market posted a MAT value growth of 8.1%, while monthly value growth for December stood at 10.6%, underscoring sustained momentum. Growth during the month was largely value-led, supported by modest unit expansion, reflecting continued price/mix improvements and increasing premiumisation across key therapy areas.

Sharing the details in her presentation on IPM 2025 Sheetal Sapale, Vice President – Commercial, Pharmarack Technologies said, “The majority of the top 20 corporates delivered encouraging value growth during the month, reinforcing their leadership role in driving overall IPM performance. Companies such as Sun Pharma, Cipla, Intas, Torrent, Lupin, Zydus, Dr. Reddy’s, Glenmark and USV reported robust double-digit value growth in December. Together, these players account for a significant share of IPM value, and their strong performance directly translated into the market’s overall growth momentum. Cipla, Intas, Torrent and Glenmark stood out with strong growth in both value and units, indicating sustained demand and portfolio strength, while Zydus and Dr. Reddy’s achieved solid value growth despite muted or negative unit trends, highlighting pricing- and mix-led expansion”.

Sheetal Sapale further noted that among corporates ranked 21–40, growth was more selective but remained encouraging. La Renon, Ajanta Pharma, Indoco Remedies, Bayer and Nutricia delivered double-digit value growth, outperforming peers, while

Corona Remedies also posted strong value and unit growth, reflecting traction in chronic segments. In contrast, Alembic, Cadila and Himalaya experienced pressure on both value and units, pointing to portfolio- or competition-led challenges.

Overall, she said top corporates continue to anchor IPM growth, with leadership companies demonstrating resilience and consistency. The continued trend of value growth outpacing unit growth highlights the increasing role of price hikes, premium brands, and specialty and chronic therapies. Performance divergence within the 21–40 rank bracket further suggests that portfolio focus and execution capability are critical for mid-sized players to outperform.

Commenting on the trend, Sheetal Sapale said, “The sustained double-digit value growth among leading corporates underscores the resilience of the Indian Pharma Market. With top players contributing a significant share to IPM, their strong performance continues to directly influence overall market growth, while selective mid-tier companies are also demonstrating encouraging momentum through focused portfolios and improved execution.”